Population pharmacokinetic-pharmacodynamic modeling of clopidogrel for dose regimen optimization based on CYP2C19 phenotypes: A proof of concept study.

Jung, Yun Seob; Jin, Byung Hak; Park, Min Soo; Kim, Choon Ok; Chae, Dongwoo

Jung, Yun Seob; Jin, Byung Hak; Park, Min Soo; Kim, Choon Ok; Chae, Dongwoo.

Afiliação

Jung YS; Department of Convergence Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.
Jin BH; Department of Clinical Pharmacology, Severance Hospital, Yonsei University Health System, Seoul, Korea.
Park MS; Department of Clinical Pharmacology, Severance Hospital, Yonsei University Health System, Seoul, Korea.
Kim CO; Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea.
Chae D; Department of Clinical Pharmacology, Severance Hospital, Yonsei University Health System, Seoul, Korea.

CPT Pharmacometrics Syst Pharmacol ; 13(1): 29-40, 2024 Jan.

Article em En | MEDLINE | ID: mdl-37775990

Assuntos

Polimorfismo Genético; Ticlopidina; Humanos; Masculino; Clopidogrel; Citocromo P-450 CYP2C19/genética; Citocromo P-450 CYP2C19/metabolismo; Genótipo; Fenótipo; Estudo de Prova de Conceito; Estudos Prospectivos; Ticlopidina/análogos & derivados; Ensaios Clínicos Fase I como Assunto

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Limite: Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google